WO1991004014A1 - Method for transporting compositions across the blood brain barrier - Google Patents
Method for transporting compositions across the blood brain barrier Download PDFInfo
- Publication number
- WO1991004014A1 WO1991004014A1 PCT/US1990/005349 US9005349W WO9104014A1 WO 1991004014 A1 WO1991004014 A1 WO 1991004014A1 US 9005349 W US9005349 W US 9005349W WO 9104014 A1 WO9104014 A1 WO 9104014A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- brain
- transferrin
- liposomes
- insulin
- blood
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A63—SPORTS; GAMES; AMUSEMENTS
- A63F—CARD, BOARD, OR ROULETTE GAMES; INDOOR GAMES USING SMALL MOVING PLAYING BODIES; VIDEO GAMES; GAMES NOT OTHERWISE PROVIDED FOR
- A63F3/00—Board games; Raffle games
- A63F3/06—Lottos or bingo games; Systems, apparatus or devices for checking such games
- A63F3/065—Tickets or accessories for use therewith
- A63F3/0685—Tickets or accessories for use therewith having a message becoming legible after a chemical reaction or physical action has taken place, e.g. applying pressure, heat treatment, spraying with a substance, breaking microcapsules
Definitions
- This barrier consists of uniform, tight junctions between adjacent endothelial cells lining brain capillaries. These junctions prevent the penetration into the brain of many water-soluble molecules. In addition, there is a relative absence of the intracellular bulk transport vesicles that shuttle molecules across endothelial cells in other organs. These barriers prevent the entry into the brain of a wide variety of potentially therapeutic compounds administered to the systemic circulation.
- the blood-brain barrier prevents certain nerotransmitters, such as dopamine, and most macromolecules, such as nerve growth factors, from entering the brain from the circulation.
- nerotransmitters such as dopamine
- macromolecules such as nerve growth factors
- One method proposed for delivering non-penetrating drugs to the brain is to chemically link the drug to a carrier compound that is capable of penetrating the blood-brain barrier.
- the penetrating compounds that have been proposed for use as carriers include small, lipid soluble molecules, such as modified dihydropyridines (Bodor, 1987, Ann. N.Y. Acad. Sci. 507: 289-306), or compounds that enter the brain through a specific transport system in brain endothelial cells, such as the transport systems for transferrin, insulin, and insulin ⁇ like growth factors I and II (Pardridge, 1988, Ann. N.Y. Acad. Sci. 529: 50-60).
- This proposed method is subject to two serious drawbacks the may prevent delivery to the brain of a wide range of therapeutic agents.
- the drug must retain its activity when chemically coupled to the carrier or there must be an endogenous and accessible brain enzyme able to uncouple the drug and carrier once they are inside the brain.
- large drugs for example macromolecules such as nerve growth factors, are very likely to dominate the chemical properties of the drug-carrier combination and prevent penetration of the combination into the brain.
- liposomes targeted to endogenous brain transport systems that will be used to encapsulate and deliver normally non-penetrating therapeutic agents to the brain. Since the therapeutic agents will be encapsulated in liposomes, they will be protected from enzymatic inactivation in the blood. Moreover, there will be no need to chemically couple these therapeutic agents to the carrier and chemically uncouple them in the brain. In addition, liposomes are capable of delivering large macromolecules, such as nerve growth factors, that would be unlikely to penetrate the brain when chemically coupled to a carrier molecule.
- the liposomes of the invention are targeted by the addition to the outside layer of the liposome of one or more molecules that are normally transported across the blood- brain barrier.
- transported molecules include, but are not limited to, transferrin, insulin, and insulin-like growth factors I and II as described by Fishman et al., 1987, J. Neurosci. Res. 18:299-304; and Frank et al., 1986, Diabetes 35:654-661, each of which is specifically incorporated herein by reference.
- Each endogenous transport system consists of specific membrane receptors on the endothelial cell surface to which the transported molecule binds, followed by mechanisms for internationalization of the molecule into an intracellular vesicle, and expulsion of the contents of the vesicle into the brain as described by Deutry-Varsat et al., 1987, J. Neurosci. Res. 18:299-304; Klausner et al., 1983, J. Biol. Chem. 258: 4715-4724; and Duffy et al., 1987, each of which is specifically incorporated by reference herein.
- the liposomes are attached to the transport systems by coupling to their external surface either one of the transported molecules mentioned above (transferrin, insulin, or insulin ⁇ like growth factors) or antibodies directed to the specific brain endothelial cell receptors for these transported molecules.
- Such coupling methods are described, for example, by Schneider et al., 1984, Nature 311: 675-678 specifically incorporated herein by reference.
- the invention consists of methods for delivering therapeutic and diagnostic agents to the brain across the blood brain barrier.
- agents are delivered to the brain by encapsulating them in liposomes targeted to any of a number of endogenous brain transport systems that transport specific ligands across the blood brain barrier.
- the liposomes are targeted to such endogenous transport systems by coupling to their outer surface either the specifically- transported ligand or antibodies to the brain endothelial cell receptor for the ligand.
- Examples of such liposome- targeting molecules are the speci.fically-transported proteins transferrin, insulin, or insulin-like growth factors I and II and antibodies to the receptors for transferrin, insulin, or embodiments of this invention and, together with the descrip serves to explain the principles of the invention.
- Figure 1 illustrates the results of a competition bindi experiment described in Example 1.
- the present invention relates to t of targeted liposomes to deliver therapeutic and/or diagnost agents across the blood-brain barrier.
- the liposomes may be prepared by any of a wide variety of standard methods for producing stable, unilamellar liposomes of uniform internal diameter.
- liposomes are composed saturated phospholipids and cholesterol in relative proporti suitable to produce stable liposomes.
- the liposomes also co a modified lipid that is capable of covalently linking a var of targeting molecules to the external liposome surface.
- the covalent-linker lipid is MPB-PE.
- the liposomes are composed of distearo phosphatidylcholine, cholesterol, and MPB-PE (N-[4-(p aleimidophenyl) butryl] phosphatidylethanolamine) in the ra molar of 1:1:0.068, assuming the final composition reflects initial reaction mixture.
- liposomes are generated by passage either through a micropore membrane or through a microfluidizer generate unilamellar liposomes of uniform diameter. Examples of these methods may be found in Klimchak and Lank, 1988 Biopharmaceutics FEB:18-21: and Olsen et al., 1979, Bioche . Biophvs. Acts 557:9-23. each of which is specifically incorporated herein by reference.
- the liposomes are targeted for passage through the blood-brain barrier by the coupling, to the outside of the liposome, of molecules which are actively transported across the blood-brain barrier. These transported molecules are added to the outside of intact liposomes and become covalently linked under appropriate reaction conditions to a suitably modified lipid incorporated into the liposome.
- suitable transport substances include, but are not limited to, transferrin, insulin, insulin-like growth factor 1 (IGF-I), insulin-like growth factor II (IGF-II), and antibodies against specific brain endothelial cell receptors for transferrin, insulin, IGF-I, and IGF-II.
- liposomes are covalently coupled through the modified lipid N-[4-p-maleimidophenyl) butyrl] phosphatidylethanolamine (MPB-PE) to iron-saturated transferrin on the surface.
- MPB-PE modified lipid N-[4-p-maleimidophenyl) butyrl] phosphatidylethanolamine
- transferrin-coated liposomes competed effectively with free transferrin for the transferrin receptors on human cells (Example 1, Figure 1).
- transferrin-coated liposomes were also able to increase the penetration into the brain of a radiolabeled tracer (Example 2, Table 1) .
- a wide variety of therapeutic agents are envisioned for encapsulation within the liposomes of this invention. These include: protein neurotrophic factors (for example, nerve growth factor) to treat brain injury and neurodegenerative diseases; enzymes to replace enzymatic activities lost through genetic defects where the loss causes severe metabolic storage diseases such as Tay-Sachs disease;
- SUBSTIT neurotransmitters and neuromodulators such as dopamine and jg-endorphin, that would be useful for treating Parkinson's disease and intractable pain, respectively, or conditions including disorders of movement, cognition, and behavior.
- antibiotics for treating infectious diseases such as neurosyphilis or AIDS, where Penetration into the brain of systemically administered antibiotics is presently a block to treatment; chemotherapeutic agents for treating brain tumors with agents that do not reach the tumor in sufficient amounts when tolerable doses are administered systemically; and diagnostic agents. such as specific contrast media for brain imaging, that are currently not used because of poor penetration into the brain upon systemic administration.
- Example 1 Method for Producing Liposomes
- the following lipids are dissolved in 25ml chloroform and evaporated to dryness as a thin film in the bottom of a round-bottomed flask: 300mmol disearoyl phosphatidylcholine, 300mmol cholesterol, and 20.4 mmol N-[4-(p-maleimidophenyl) butyrl] phosphatidylethanolamine (MPB-PE).
- MPB-PE contains a reactive group capable of coupling to a wide variety of proteins. (Martin and Papahadjopoulos, 1982, J. Biol. Chem. 257:286-288).
- the material to be encapsulated is dissolved in Buffer I consisting of 108mM NaCl, 35mM Na 2 HP0 4 , 20mM citric acid, ImM EDTA, pH 4.5.
- Buffer I consisting of 108mM NaCl, 35mM Na 2 HP0 4 , 20mM citric acid, ImM EDTA, pH 4.5.
- the low pH prevents premature hydrolysis of the covalent linking group on MPB-PE.
- Lipids are swollen in this solution for 3 hours, then the solution is passed seven times through a microfluidizer MHO as described by Teagarden et al. in Pharmaceutical Res. 5.: 482-487 (1988) at a final nitrogen pressure of 10,000 psi to create unilamellar liposomes in a narrow size range with an average diameter of approximately lOOnm.
- the unilamellar nature of the liposomes was confirmed by X-ray diffraction and the size distribution determined by light scattering.
- the mixture is passed over a Sephadex G150 column equilibrated with buffer I.
- the liposomes emerge from the column in the void volume.
- the liposomes are deaerated under argon for 2 hours.
- Ten mg of iron-saturated transferrin is added dissolved in Ringer's salt solution.
- the pH is raised to 7.0 at which pH the coupling group on MPB-PE is activated, and the reaction allowed to stand under argon overnight at 4°C.
- Reactive groups on MPB-PE that do not couple to transferrin during this step including those molecules of MPB-PE whose reactive groups face the interior of the liposome, are hydrolyzed and inactivated when oxygen is reintroduced during subsequent processing.
- Transferrin- coupled liposomes are separated from free, unreacted transferrin by a second passage of the reaction mixture through a G-150 column equilibrated with Ringer's salt solution. The amount of transferrin is measured in each fraction emerging from the column by standard protein assay in order to calculate the amount of unincorporated transferrin and the number of coupled transferrin molecules per liposome.
- an aliquot of each liposome preparation can be stored at 4°C for various lengths of time, then passed over a G-150 sizing column to determine what proportion of the transferrin and encapsulated drug emerge in the liposome vs. the non-liposome fractions.
- a competition assay can be run comparing the ability of transferrin-coupled liposomes to .compete with free transferrin for the transferrin receptor.
- Figure 1 illustrates the results of one such competition assay. The experiment consists of introducing a fixed amount (InM) of
- Test wells also contain increasing concentrations of one of the following: free unlabeled transferrin, transferrin-coupled liposomes, or liposomes without transferrin coupled to their outer surface.
- the reduction in the amount of 125I-labeled transferrin bound was measured in triplicate tubes.
- Figure 1 plots the 125I-labeled transferrin bound in each tube (average +. standard deviation) vs. the log of the final molar concentration of either liposomes or unlabeled transferrin. The results indicate that transferrin-coupled liposomes can bind well to the transferrin receptor.
- Sprague-Dawley rate are anaestetized with Nembutal and cleared of blood by perfusion through an aortic cannula with
- Buffer II consisting of Ringer's salt solution containing
- bovine serum albumin 0.2% bovine serum albumin.
- the subclavian arteries are tied off and the perfusion continued to the remainder of the upper half of the body.
- the perfusate is circulated at 6-8ml/min.
- the p0 2 is maintained at 210 ⁇ 20 and 165 ⁇ 2mm Hg in the infusate and exfusate, respectively.
- the pC0 2 typically ranges from approximately 12 +.12 in the infusate to 22 +.4mm
- Transferrin-coupled liposomes are prepared with either a radiolabeled tracer, such as an 125I-labeled peptide, or a histochemical tracer, such as a biotinylated peptide, encapsulated inside them.
- a radiolabeled tracer such as an 125I-labeled peptide
- a histochemical tracer such as a biotinylated peptide
- Buffer II After the blood is cleared from an animal, typically lOmin after perfusion has begun, the liposomes are added and perfusion continued for various times up to 60min.
- the brain microvasculature is isolated by the method of Brandel
- brains are removed and homogenized.
- the homogenate is passed through nylon meshes of decreasing pore diameter.
- the material captured on the final nylon filter consists solely of thin brain vascular elements, devoid of smooth muscle cells (Fishman et al., 1987, J.
- the amount of liposome encapsulated radiolabeled tracer that appears in this vascular fraction is multiplied by a predetermined correction factor in order to calculate the total amount of encapsulated radiolabeled tracer in the brain vasculature.
- the correction factor corresponds to the percentage of the total brain vasculature typically recovered in the final fraction retained on nylon mesh and is determined as described in Fishman et al., 1987
- the fraction of the brain homogenate that is not retained on the final passage through nylon mesh is the brain parenchymal fraction.
- the total amount of liposome- encapsulated radiolabeled tracer in this fraction measures the amount delivered to the brain.
- the transport of liposome-encapsulated material into the brain is also demonstrated by direct localization of transported material in brain sections using histochemistry.
- transferrin-coupled liposomes containing a biotinylated peptide La Rochelle and Froehner, 1986, J. Biol. Chem. 261:5270-5274
- the brain is fixed by continued perfusion with 4% paraformaldehyde for light microscopy or 4% paraformaldehyde and 0.25% glutaraldehyde for electron microscopy.
- Various brain regions are dissected, embedded in Epon-Araldite and sectioned on an ultramicrotome for electron microscopy.
Abstract
Methods for delivering therapeutic and diagnostic agents to the brain across the blood-brain barrier are disclosed. Such agents are delivered to the brain by encapsulating them in liposomes targeted to endogenous brain transport systems that transport specific ligands across the blood-brain barrier. Examples of such liposome-targeting molecule are the specifically-transported proteins transferrin, insulin, or insulin-like growth factors I and II and antibodies to the receptors for transferrin, insulin, or insulin-like growth factors I and II.
Description
DESCRIPTION
Method for Transporting Compositions Across the Blood Brain Barrier
Background of the Invention
There are many instances in which delivery of therapeutic agents, for example drugs, or diagnostic agents to the brain are desired. However, it has been very difficult to deliver these agents to the brain directly from the systemic circulation because of the "blood-brain barrier. "
This barrier consists of uniform, tight junctions between adjacent endothelial cells lining brain capillaries. These junctions prevent the penetration into the brain of many water-soluble molecules. In addition, there is a relative absence of the intracellular bulk transport vesicles that shuttle molecules across endothelial cells in other organs. These barriers prevent the entry into the brain of a wide variety of potentially therapeutic compounds administered to the systemic circulation.
As an example, the blood-brain barrier prevents certain nerotransmitters, such as dopamine, and most macromolecules, such as nerve growth factors, from entering the brain from the circulation. The lack of penetration of these compounds into the brain upon systemic administration severely limits their use in the treatment of neurodegenerative diseases, such as Parkinson's and Alzheimer's diseases, respectively.
For those reasons, methods have been sought to penetrate the blood-brain barrier and deliver therapeutic agents directly to the brain from the circulation. One method proposed for delivering non-penetrating drugs to the brain is to chemically link the drug to a carrier compound that is capable of penetrating the blood-brain barrier. The penetrating compounds that have been proposed for use as carriers include small, lipid soluble molecules, such as
modified dihydropyridines (Bodor, 1987, Ann. N.Y. Acad. Sci. 507: 289-306), or compounds that enter the brain through a specific transport system in brain endothelial cells, such as the transport systems for transferrin, insulin, and insulin¬ like growth factors I and II (Pardridge, 1988, Ann. N.Y. Acad. Sci. 529: 50-60).
This proposed method is subject to two serious drawbacks the may prevent delivery to the brain of a wide range of therapeutic agents. First, either the drug must retain its activity when chemically coupled to the carrier or there must be an endogenous and accessible brain enzyme able to uncouple the drug and carrier once they are inside the brain. Secondly, large drugs, for example macromolecules such as nerve growth factors, are very likely to dominate the chemical properties of the drug-carrier combination and prevent penetration of the combination into the brain.
An additional potential drawback to this proposed delivery system is the inability to protect sensitive drugs from being inactivated in the blood. For example, many potentially therapeutic peptides, such as analgesic - endorphins, are rapidly degraded in the blood (Houghten et al., 1980, Proc. Natl. Acad. Sci. , U.S.A. 77: 4588-4591).
The present inventors have overcome these problems through the use of liposomes targeted to endogenous brain transport systems that will be used to encapsulate and deliver normally non-penetrating therapeutic agents to the brain. Since the therapeutic agents will be encapsulated in liposomes, they will be protected from enzymatic inactivation in the blood. Moreover, there will be no need to chemically couple these therapeutic agents to the carrier and chemically uncouple them in the brain. In addition, liposomes are capable of delivering large macromolecules, such as nerve growth factors, that would be unlikely to penetrate the brain when chemically coupled to a carrier molecule.
The liposomes of the invention are targeted by the addition to the outside layer of the liposome of one or more
molecules that are normally transported across the blood- brain barrier. Such transported molecules include, but are not limited to, transferrin, insulin, and insulin-like growth factors I and II as described by Fishman et al., 1987, J. Neurosci. Res. 18:299-304; and Frank et al., 1986, Diabetes 35:654-661, each of which is specifically incorporated herein by reference. Each endogenous transport system consists of specific membrane receptors on the endothelial cell surface to which the transported molecule binds, followed by mechanisms for internationalization of the molecule into an intracellular vesicle, and expulsion of the contents of the vesicle into the brain as described by Deutry-Varsat et al., 1987, J. Neurosci. Res. 18:299-304; Klausner et al., 1983, J. Biol. Chem. 258: 4715-4724; and Duffy et al., 1987, each of which is specifically incorporated by reference herein. The liposomes are attached to the transport systems by coupling to their external surface either one of the transported molecules mentioned above (transferrin, insulin, or insulin¬ like growth factors) or antibodies directed to the specific brain endothelial cell receptors for these transported molecules. Such coupling methods are described, for example, by Schneider et al., 1984, Nature 311: 675-678 specifically incorporated herein by reference.
Summary of the Invention The invention consists of methods for delivering therapeutic and diagnostic agents to the brain across the blood brain barrier. Such agents are delivered to the brain by encapsulating them in liposomes targeted to any of a number of endogenous brain transport systems that transport specific ligands across the blood brain barrier. The liposomes are targeted to such endogenous transport systems by coupling to their outer surface either the specifically- transported ligand or antibodies to the brain endothelial cell receptor for the ligand. Examples of such liposome- targeting molecules are the speci.fically-transported proteins transferrin, insulin, or insulin-like growth factors I and II and antibodies to the receptors for transferrin, insulin, or
embodiments of this invention and, together with the descrip serves to explain the principles of the invention.
DESCRIPTION OF THE DRAWINGS
Figure 1 illustrates the results of a competition bindi experiment described in Example 1.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Reference will now be made in detail to the presently preferred embodiments of the invention, which, together with following examples, serve to explain the principles of the inventio .
As noted previously, the present invention relates to t of targeted liposomes to deliver therapeutic and/or diagnost agents across the blood-brain barrier. The liposomes may be prepared by any of a wide variety of standard methods for producing stable, unilamellar liposomes of uniform internal diameter. In a preferred embodiment, liposomes are composed saturated phospholipids and cholesterol in relative proporti suitable to produce stable liposomes. The liposomes also co a modified lipid that is capable of covalently linking a var of targeting molecules to the external liposome surface. In preferred embodiment, the covalent-linker lipid is MPB-PE. preferred embodiment, the liposomes are composed of distearo phosphatidylcholine, cholesterol, and MPB-PE (N-[4-(p aleimidophenyl) butryl] phosphatidylethanolamine) in the ra molar of 1:1:0.068, assuming the final composition reflects initial reaction mixture.
In preferred embodiments, liposomes are generated by passage either through a micropore membrane or through a microfluidizer generate unilamellar liposomes of uniform diameter. Examples of these methods may be found in Klimchak and Lank, 1988 Biopharmaceutics FEB:18-21: and Olsen et al., 1979, Bioche . Biophvs. Acts 557:9-23. each of which is specifically incorporated herein by reference.
The liposomes are targeted for passage through the blood-brain barrier by the coupling, to the outside of the liposome, of molecules which are actively transported across the blood-brain barrier. These transported molecules are added to the outside of intact liposomes and become covalently linked under appropriate reaction conditions to a suitably modified lipid incorporated into the liposome. Examples of suitable transport substances include, but are not limited to, transferrin, insulin, insulin-like growth factor 1 (IGF-I), insulin-like growth factor II (IGF-II), and antibodies against specific brain endothelial cell receptors for transferrin, insulin, IGF-I, and IGF-II.
In a preferred embodiment, liposomes are covalently coupled through the modified lipid N-[4-p-maleimidophenyl) butyrl] phosphatidylethanolamine (MPB-PE) to iron-saturated transferrin on the surface. In one example of such a preferred embodiment, transferrin-coated liposomes competed effectively with free transferrin for the transferrin receptors on human cells (Example 1, Figure 1). Such transferrin-coated liposomes were also able to increase the penetration into the brain of a radiolabeled tracer (Example 2, Table 1) .
A wide variety of therapeutic agents are envisioned for encapsulation within the liposomes of this invention. These include: protein neurotrophic factors (for example, nerve growth factor) to treat brain injury and neurodegenerative diseases; enzymes to replace enzymatic activities lost through genetic defects where the loss causes severe metabolic storage diseases such as Tay-Sachs disease;
SUBSTIT
neurotransmitters and neuromodulators, such as dopamine and jg-endorphin, that would be useful for treating Parkinson's disease and intractable pain, respectively, or conditions including disorders of movement, cognition, and behavior. antibiotics for treating infectious diseases, such as neurosyphilis or AIDS, where Penetration into the brain of systemically administered antibiotics is presently a block to treatment; chemotherapeutic agents for treating brain tumors with agents that do not reach the tumor in sufficient amounts when tolerable doses are administered systemically; and diagnostic agents. such as specific contrast media for brain imaging, that are currently not used because of poor penetration into the brain upon systemic administration. EXAMPLES
The following Examples serve to illustrate certain of the preferred embodiments of the present invention. All articles and patents referred to in these Examples are specifically incorporated herein by reference. Example 1 - Method for Producing Liposomes
The following lipids are dissolved in 25ml chloroform and evaporated to dryness as a thin film in the bottom of a round-bottomed flask: 300mmol disearoyl phosphatidylcholine, 300mmol cholesterol, and 20.4 mmol N-[4-(p-maleimidophenyl) butyrl] phosphatidylethanolamine (MPB-PE). The MPB-PE contains a reactive group capable of coupling to a wide variety of proteins. (Martin and Papahadjopoulos, 1982, J. Biol. Chem. 257:286-288). The material to be encapsulated is dissolved in Buffer I consisting of 108mM NaCl, 35mM Na2HP04, 20mM citric acid, ImM EDTA, pH 4.5. The low pH prevents premature hydrolysis of the covalent linking group on MPB-PE.
Lipids are swollen in this solution for 3 hours, then the solution is passed seven times through a microfluidizer MHO as described by Teagarden et al. in Pharmaceutical Res. 5.: 482-487 (1988) at a final nitrogen pressure of 10,000 psi to create unilamellar liposomes in a narrow size range with
an average diameter of approximately lOOnm. The unilamellar nature of the liposomes was confirmed by X-ray diffraction and the size distribution determined by light scattering.
To separate liposomes from unincorporated materials, the mixture is passed over a Sephadex G150 column equilibrated with buffer I. The liposomes emerge from the column in the void volume. The liposomes are deaerated under argon for 2 hours. Ten mg of iron-saturated transferrin is added dissolved in Ringer's salt solution. The pH is raised to 7.0 at which pH the coupling group on MPB-PE is activated, and the reaction allowed to stand under argon overnight at 4°C. Reactive groups on MPB-PE that do not couple to transferrin during this step, including those molecules of MPB-PE whose reactive groups face the interior of the liposome, are hydrolyzed and inactivated when oxygen is reintroduced during subsequent processing. Transferrin- coupled liposomes are separated from free, unreacted transferrin by a second passage of the reaction mixture through a G-150 column equilibrated with Ringer's salt solution. The amount of transferrin is measured in each fraction emerging from the column by standard protein assay in order to calculate the amount of unincorporated transferrin and the number of coupled transferrin molecules per liposome.
To determine whether transferrin and encapsulated drug are stably associated with the liposomes, an aliquot of each liposome preparation can be stored at 4°C for various lengths of time, then passed over a G-150 sizing column to determine what proportion of the transferrin and encapsulated drug emerge in the liposome vs. the non-liposome fractions.
To determine whether the transferrin is present at the liposome surface in a form that is still capable of reacting with its specific cell surface transport-mediating receptor, a competition assay can be run comparing the ability of transferrin-coupled liposomes to .compete with free transferrin for the transferrin receptor. Figure 1 illustrates the results of one such competition assay. The
experiment consists of introducing a fixed amount (InM) of
125 I-labeled transferrin into tubes each of which contains
2x10 K562 human erytholeukemic cells that possess a high density of transferrin receptors (Kla'usner et al., 1983, J.
Biol. Chem. 258:4715-4724). Test wells also contain increasing concentrations of one of the following: free unlabeled transferrin, transferrin-coupled liposomes, or liposomes without transferrin coupled to their outer surface. The reduction in the amount of 125I-labeled transferrin bound was measured in triplicate tubes. Figure 1 plots the 125I-labeled transferrin bound in each tube (average +. standard deviation) vs. the log of the final molar concentration of either liposomes or unlabeled transferrin. The results indicate that transferrin-coupled liposomes can bind well to the transferrin receptor. Indeed, the results indicate that, on a molar basis, transferrin- coupled liposomes compete more effectively than free- transferrin for the transferrin receptor. Liposomes that had no transferrin coupled to their surface did not reduce the amount of 125I-labeled transferrin bound to the cells, indicating that such liposomes failed to compete for the transferrin receptor.
Example 2 - Protocol for Liposome Perfusions to Test Delivery
Perfusion and assessment of drug delivery across the blood-brain barrier are performed as described in Fishman et al. 1987 (J. Neurosci. Res. 18:299-304). Briefly, male 200g
Sprague-Dawley rate are anaestetized with Nembutal and cleared of blood by perfusion through an aortic cannula with
Buffer II consisting of Ringer's salt solution containing
0.2% bovine serum albumin. The subclavian arteries are tied off and the perfusion continued to the remainder of the upper half of the body. The perfusate is circulated at 6-8ml/min.
The p02 is maintained at 210 ± 20 and 165 ± 2mm Hg in the infusate and exfusate, respectively. The pC02 typically ranges from approximately 12 +.12 in the infusate to 22 +.4mm
Hg in the exfusate. The 02 consumption and C02 production are monitored continuously and do not change appreciably
during the course of perfusion. Each experimental condition is run in triplicate on three rats.
Transferrin-coupled liposomes are prepared with either a radiolabeled tracer, such as an 125I-labeled peptide, or a histochemical tracer, such as a biotinylated peptide, encapsulated inside them. The liposomes are suspended in
Buffer II. After the blood is cleared from an animal, typically lOmin after perfusion has begun, the liposomes are added and perfusion continued for various times up to 60min.
At the end of each experimental interval, fresh Buffer II is substituted for the liposome-containing perfusate and perfusion continued until none of the encapsulated tracer is detectable in the circulation, typically lO in.
To measure delivery to the brain biochemically, the brain microvasculature is isolated by the method of Brandel
(Fishman et al., 1987, J. Neurosci. Res. 18:299-304; Brandel et al., 1984, Science 185:953-955) at room temperature.
Briefly, after perfusion, brains are removed and homogenized.
The homogenate is passed through nylon meshes of decreasing pore diameter. The material captured on the final nylon filter consists solely of thin brain vascular elements, devoid of smooth muscle cells (Fishman et al., 1987, J.
Neurosci. Res. 18:299-304; Brandel et al., 1974, Science
185:953-955). The amount of liposome encapsulated radiolabeled tracer that appears in this vascular fraction is multiplied by a predetermined correction factor in order to calculate the total amount of encapsulated radiolabeled tracer in the brain vasculature. The correction factor corresponds to the percentage of the total brain vasculature typically recovered in the final fraction retained on nylon mesh and is determined as described in Fishman et al., 1987
(J. Neurosci. Res. 18:299-304).
The fraction of the brain homogenate that is not retained on the final passage through nylon mesh is the brain parenchymal fraction. The total amount of liposome- encapsulated radiolabeled tracer in this fraction measures the amount delivered to the brain. By this method one can
determine separately the amount of encapsulated material delivered to the brain parenchyma and the brain vasculature.
The transport of liposome-encapsulated material into the brain is also demonstrated by direct localization of transported material in brain sections using histochemistry. After perfusion as above with transferrin-coupled liposomes containing a biotinylated peptide (La Rochelle and Froehner, 1986, J. Biol. Chem. 261:5270-5274), the brain is fixed by continued perfusion with 4% paraformaldehyde for light microscopy or 4% paraformaldehyde and 0.25% glutaraldehyde for electron microscopy. Various brain regions are dissected, embedded in Epon-Araldite and sectioned on an ultramicrotome for electron microscopy. Sections are exposed to avidin-horse radish peroxidase (avidin-HRP) which binds exclusively to the sites where biotinylated peptide has localized. The complex of avidin-HRP and biotinylated peptide is visualized by the production of a "visible" HRP reaction product in the light or electron microscope as described (Connor and Fine 1986, Brain Res. 368:319-328).
TABLE 1
LIPSOMES N VASCULAR PELLET PARENCHYMAL SUP TRANSFERRIN 2 1,095 + 61 cpm 1,645 = 389 cpm OVALBUMIN 2 323 + 11° cpm 42 = 167 cpm
TABLE 1: DELIVERY OF RADIOLABELED TRACER BY
TRANSFERRIN VS. OVALBUMIN COATED LIPSOMES
Table 1 illustrates the results of an experiment in which 2.3x10 14 liposomes (average diameter = 45.2nm)
6 32 containing 2.0x10 cpm of P-oligonucleotide tracer and coupled to 489 transferrins or 590 ovalbumins per liposome were perfused through the cerebral circulation of anaesthetized rate for 45 minutes.. Perfusion was continued for another 10 minutes in Ringer's without liposomes, then the brain was removed and fractionated into a representative
vascular compartment and a brain parenchymal compartment, as described above. Two rats were perfused with liposomes coated with iron-saturated rat transferrin, while two rats were perfused with liposomes coated with a control nontransported protein, ovalbumin.
The results indicate that the brain parenchymal and vascular compartments contained at least 3-4 fold more radioactive tracer when transferrin-coated liposomes were used. These results suggest that delivery to the brain occurred and was transferrin dependent. The amount of radioactivity in the parenchymal compartment corresponds to the delivery of the tracer inside greater than 1 in 2,000 liposomes.
This amount of transport, although by no means the maximum that should be achievable with this technique when optimized, is pharmacologically significant. Transport of the contents of 1 in 2,000 liposome would allow delivery of about lOOng of 3-endorphin to the brain, making the conservative assumption that 200μg had been encapsulated in a dose of 1x10 15 liposomes. lOOng of ø-endorphin produces detectable analgesia when injected into the brain ventricles of rats (Tiseo et al., 1988, J. Pharmacol. Exp. Ther.
246:449-453).
It would be apparent to those skilled in the art that various modifications and variations can be made to the processes and products of the present invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.
Claims
1. A method for the delivery of diagnostic or therapeutic agents across the blood-brain barrier comprising:
(a) encapsulation of the therapeutic or diagnostic agent to be delivered in a liposome;
(b) targeting the liposome by attachment to its external surface of either (i) a molecule which is actively transported across the blood-brain barrier or (ii) antibodies to the specific brain endothelial cell receptors for molecules which are actively transported across the blood- brain barrier;
(c) administering to a mammal of the targeted liposomes containing the diagnostic or therapeutic agent to be delivered.
2. The targeted liposome of claim 1 wherein the targeting molecule is selected from the group consisting of transferrin, insulin, or insulin-like growth factors I and II, and/or antibodies to the brain endothelial cell receptors for transferrin, insulin, and/or insulin-like growth factors I and II.
3. The targeted liposomes of claim 1 wherein the therapeutic agent is nerve growth factor.
4. The targeted liposomes of claim 1 wherein the therapeutic agent is ^-endorphin.
5. The targeted liposomes of claim 1 wherein the therapeutic agent is dopamine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41031989A | 1989-09-21 | 1989-09-21 | |
US410,319 | 1989-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991004014A1 true WO1991004014A1 (en) | 1991-04-04 |
Family
ID=23624209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/005349 WO1991004014A1 (en) | 1989-09-21 | 1990-09-21 | Method for transporting compositions across the blood brain barrier |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU6501390A (en) |
CA (1) | CA2025907A1 (en) |
WO (1) | WO1991004014A1 (en) |
Cited By (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994002178A1 (en) * | 1992-07-27 | 1994-02-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting of liposomes to the blood-brain barrier |
WO1994017821A1 (en) * | 1993-02-09 | 1994-08-18 | Basf Aktiengesellschaft | Use of thrombine inhibitors for controlling neurodegenerative diseases |
WO1995007092A1 (en) * | 1993-09-10 | 1995-03-16 | The University Of Medicine And Dentistry Of New Jersey | Blood-brain barrier transporters of neurological agents |
US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
US5948384A (en) * | 1990-09-14 | 1999-09-07 | Syngenix Limited | Particulate agents |
US6117454A (en) * | 1994-02-28 | 2000-09-12 | Medinova Medical Consulting Gmbh | Drug targeting to the nervous system by nanoparticles |
US6207153B1 (en) | 1996-05-22 | 2001-03-27 | Viventia Biotech, Inc. | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
US6339060B1 (en) | 1990-11-01 | 2002-01-15 | Oregon Health & Science University | Conjugate of biologically active compound and polar lipid conjugated to a microparticle for biological targeting |
US6562318B1 (en) | 1990-09-14 | 2003-05-13 | Syngenix Limited | Particular agents |
US6569664B1 (en) | 1996-11-06 | 2003-05-27 | The Regents Of The University Of California | Native TNF receptor releasing enzyme |
EP1446007A1 (en) * | 2001-10-16 | 2004-08-18 | Symbiontics, Inc. | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
US6919067B2 (en) | 1991-09-13 | 2005-07-19 | Syngenix Limited | Compositions comprising a tissue glue and therapeutic agents |
US7115722B1 (en) | 1997-05-22 | 2006-10-03 | Viventia Biotech, Inc. | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
WO2006126208A2 (en) * | 2005-05-26 | 2006-11-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier |
US7217796B2 (en) | 2002-05-24 | 2007-05-15 | Schering Corporation | Neutralizing human anti-IGFR antibody |
US7326567B2 (en) | 2003-11-12 | 2008-02-05 | Schering Corporation | Plasmid system for multigene expression |
US7396811B2 (en) | 2001-04-30 | 2008-07-08 | Zystor Therapeutics, Inc. | Subcellular targeting of therapeutic proteins |
WO2008134828A2 (en) | 2007-05-04 | 2008-11-13 | Katholieke Universiteit Leuven | Tissue degeneration protection |
US7462642B2 (en) | 2002-03-22 | 2008-12-09 | Cancer Research Technology Limited | Anti-cancer combinations |
US7510830B2 (en) | 2000-07-28 | 2009-03-31 | Cancer Research Technology Limited | Cancer treatment by combination therapy |
US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US7585893B2 (en) | 2002-11-01 | 2009-09-08 | Cancer Research Technology Limited | Anti-cancer composition comprising DMXAA or related compound |
US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
WO2010035261A2 (en) | 2008-09-29 | 2010-04-01 | Ben Gurion University Of The Negev Research And Development Authority | Amyloid beta-peptides and methods of use thereof |
US7723056B1 (en) | 1997-10-16 | 2010-05-25 | The University Of Manchester | Particles |
US7785856B2 (en) | 2004-02-10 | 2010-08-31 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
US7795232B1 (en) | 2000-08-25 | 2010-09-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
WO2010108665A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
US7811562B2 (en) | 2004-12-03 | 2010-10-12 | Schering Corporation | Biomarkers for pre-selection of patients for anti-IGF1R therapy |
US7863320B2 (en) | 2001-09-03 | 2011-01-04 | Cancer Research Technology Limited | Anti-cancer combinations |
EP2274011A2 (en) * | 2008-04-17 | 2011-01-19 | Banyan Biomarkers, Inc. | An antibody bound synthetic vesicle containing active agent molecules |
EP2274978A1 (en) | 2003-09-12 | 2011-01-19 | Tercica, Inc. | Methods for treatment of insulin-like growth factor-I(IGF-I) deficiency |
EP2281828A2 (en) | 2000-12-29 | 2011-02-09 | The Kenneth S. Warren Institute, Inc. | Compositions comprising modified erythropoietin |
WO2011063980A1 (en) | 2009-11-26 | 2011-06-03 | Inflarx Gmbh | Anti-c5a binding moieties with high blocking activity |
WO2011070177A2 (en) | 2009-12-11 | 2011-06-16 | Baltic Technology Development, Ltd. | Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators |
US7981864B2 (en) | 2001-10-16 | 2011-07-19 | Biomarin Pharmaceutical Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
US8017735B2 (en) | 2003-11-21 | 2011-09-13 | Schering Corporation | Anti-IGFR1 antibody therapeutic combinations |
EP2371855A1 (en) | 2005-08-05 | 2011-10-05 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and uses thereof |
WO2012061907A2 (en) | 2010-11-10 | 2012-05-18 | Katholieke Universiteit Leuven | Osteoclast activity |
WO2013093891A1 (en) | 2011-12-22 | 2013-06-27 | Nuvo Research Gmbh | Liposomal chlorite or chlorate compositions |
US8835654B2 (en) | 2004-12-22 | 2014-09-16 | Bhi Limited Partnership | Method and compositions for treating amyloid-related diseases |
WO2014143614A1 (en) | 2013-03-11 | 2014-09-18 | Jan Remmereit | Lipid compositions containing bioactive fatty acids |
WO2014140934A2 (en) | 2013-03-11 | 2014-09-18 | Life Science Nutrition As | Natural lipids containing non-oxidizable fatty acids |
US8895303B2 (en) | 2006-11-13 | 2014-11-25 | Charite-Universitatsmedizin Berlin | Method of cell culture and method of treatment comprising a vEPO protein variant |
US20150125497A1 (en) * | 2003-04-28 | 2015-05-07 | Children's Hospital Medical Center | Saposin C-DOPS: A Novel Anti-Tumor Agent |
WO2015098989A1 (en) | 2013-12-25 | 2015-07-02 | Jcrファーマ株式会社 | Novel anti-transferrin receptor antibody that passes through blood-brain barrier |
EP2933264A2 (en) | 2008-01-22 | 2015-10-21 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
US9198733B2 (en) | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
US9283051B2 (en) | 2008-04-29 | 2016-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
US9469683B2 (en) | 2008-05-07 | 2016-10-18 | Biomarin Pharmaceutical Inc. | Lysosomal targeting peptides and uses thereof |
US9499480B2 (en) | 2006-10-12 | 2016-11-22 | Bhi Limited Partnership | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
US9598691B2 (en) | 2008-04-29 | 2017-03-21 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation to create tissue scaffolds |
US9764145B2 (en) | 2009-05-28 | 2017-09-19 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
WO2018050848A1 (en) | 2016-09-15 | 2018-03-22 | Universität Stuttgart | Antigen binding protein against her3 |
WO2018087720A1 (en) | 2016-11-14 | 2018-05-17 | Novartis Ag | Compositions, methods, and therapeutic uses related to fusogenic protein minion |
US9988427B2 (en) | 2005-05-13 | 2018-06-05 | Charite Universitaetsmedizen-Berlin | Erythropoietin variants |
EP3345545A1 (en) | 2011-04-21 | 2018-07-11 | The Regents of The University of California | Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles |
WO2018184739A1 (en) | 2017-04-03 | 2018-10-11 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of c5a activity |
US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
WO2018226992A1 (en) | 2017-06-07 | 2018-12-13 | Adrx, Inc. | Tau aggregation inhibitors |
US10154874B2 (en) | 2008-04-29 | 2018-12-18 | Virginia Tech Intellectual Properties, Inc. | Immunotherapeutic methods using irreversible electroporation |
WO2018234118A1 (en) | 2017-06-23 | 2018-12-27 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of c5a activity |
WO2019036725A2 (en) | 2017-08-18 | 2019-02-21 | Adrx, Inc. | Tau aggregation peptide inhibitors |
US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
US10245105B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Electroporation with cooling to treat tissue |
US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
US10292755B2 (en) | 2009-04-09 | 2019-05-21 | Virginia Tech Intellectual Properties, Inc. | High frequency electroporation for cancer therapy |
US10335224B2 (en) | 2000-08-17 | 2019-07-02 | Angiodynamics, Inc. | Method of destroying tissue cells by electroporation |
US10463426B2 (en) | 2001-08-13 | 2019-11-05 | Angiodynamics, Inc. | Method for treating a tubular anatomical structure |
US10471254B2 (en) | 2014-05-12 | 2019-11-12 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
WO2020055768A1 (en) | 2018-09-10 | 2020-03-19 | Cold Spring Harbor Laboratory | Methods for treating pancreatitis |
US10694972B2 (en) | 2014-12-15 | 2020-06-30 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
WO2020182384A1 (en) | 2019-03-11 | 2020-09-17 | Inflarx Gmbh | Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor |
WO2021190770A1 (en) | 2020-03-27 | 2021-09-30 | Inflarx Gmbh | INHIBITORS OF C5A FOR THE TREATMENT OF CORONA VIRUS Infection |
US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
US11464868B2 (en) | 2017-04-03 | 2022-10-11 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5A activity |
US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
US11723710B2 (en) | 2016-11-17 | 2023-08-15 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
US11931096B2 (en) | 2010-10-13 | 2024-03-19 | Angiodynamics, Inc. | System and method for electrically ablating tissue of a patient |
US11952568B2 (en) | 2019-04-05 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of biphasic electrical pulses for non-thermal ablation |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4480041A (en) * | 1982-07-09 | 1984-10-30 | Collaborative Research, Inc. | Use of phosphotriester intermediates for preparation of functionalized liposomes |
US4621023A (en) * | 1982-10-15 | 1986-11-04 | Parfums Christian Dior | Method of homogenizing dispersions of hydrated lipidic lamellar phases and suspensions obtained by the said method |
US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
JPH01149718A (en) * | 1987-12-07 | 1989-06-12 | Yoshikatsu Eto | Liposome preparation easily passing through blood-brain barrier |
US4946787A (en) * | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
-
1990
- 1990-09-21 CA CA 2025907 patent/CA2025907A1/en not_active Abandoned
- 1990-09-21 WO PCT/US1990/005349 patent/WO1991004014A1/en unknown
- 1990-09-21 AU AU65013/90A patent/AU6501390A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4480041A (en) * | 1982-07-09 | 1984-10-30 | Collaborative Research, Inc. | Use of phosphotriester intermediates for preparation of functionalized liposomes |
US4621023A (en) * | 1982-10-15 | 1986-11-04 | Parfums Christian Dior | Method of homogenizing dispersions of hydrated lipidic lamellar phases and suspensions obtained by the said method |
US4946787A (en) * | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
JPH01149718A (en) * | 1987-12-07 | 1989-06-12 | Yoshikatsu Eto | Liposome preparation easily passing through blood-brain barrier |
Non-Patent Citations (7)
Title |
---|
A.G. GITMAN et al., "Targeting of Loaded Sendai Virus Envelopes by Covalently Attached Insulin Molecules...", Proc. Natl. Acad. Sci. USA, November 1985, Vol. 82, 7309-7313, (Eng.). * |
CHEMICAL ABSTRACTS, Volume 102, No. 3, 17315d, issued 1984, (Columbus, Ohio, USA), T. OSANAI et al., "Suppression of Experimental Allergic Encephalomyelitis (EAE) with Liposome-Encapsulated Protease Inhibitor..."; & NEUROCHEM. RES., 9(10), 1407-16-5, (Eng.). * |
CHEMICAL ABSTRACTS, Volume 103, No. 22, 183502c, issued 1984, (Columbus, Ohio, USA), K. YAGI, "Enzyme Replacement Therapy Using Liposomes of Novel Composition"; & ICSU SHORT REPORT, 7 (Adv. Gene Technology), 120-123, (Eng.). * |
CHEMICAL ABSTRACTS, Volume 109, No. 14, 115952y, issued 1988, (Columbus, Ohio, USA), F. UMEZAWA et al., "Liposome Targeting to Mouse Brain: Mannose as a Recognition Marker"; & BIOCHEM. BIOPHYS. RES. COMMUN., 153(3), 1038-44 (Eng.). * |
CHEMICAL ABSTRACTS, Volume 112, No. 6, 42271a, issued 1989, (Columbus, Ohio, USA), T. OSANAI et al., "Blood-Brain Barrier Model and Liposome Method"; & KAGAKU (KYOTO), 44(9), 624-5, (Eng.). * |
CHEMICAL ABSTRACTS, Volume 12, No. 16, 145572d, issued 1989, (Columbus, Ohio, USA), Y. ITO; & JP,A,1 149 718, 12 June 1989, (Eng.). * |
CHEMICAL ABSTRACTS, Volume 94, No. 11, 81079y, issued 1980, (Columbus, Ohio, USA), M. NAOI et al., "Incorporation of Enzyme Through Blood-Brain Barrier into Brain by Means of Liposomes"; & BIOCHEM. INT., 1(6), 591-6, (Eng.). * |
Cited By (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5948384A (en) * | 1990-09-14 | 1999-09-07 | Syngenix Limited | Particulate agents |
US6562318B1 (en) | 1990-09-14 | 2003-05-13 | Syngenix Limited | Particular agents |
US6339060B1 (en) | 1990-11-01 | 2002-01-15 | Oregon Health & Science University | Conjugate of biologically active compound and polar lipid conjugated to a microparticle for biological targeting |
US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
US6024977A (en) * | 1990-11-01 | 2000-02-15 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
US6858582B2 (en) | 1990-11-01 | 2005-02-22 | Oregon Health And Sciences University | Composition containing porous microparticle impregnated with biologically-active compound for treatment of infection |
US6436437B1 (en) | 1990-11-01 | 2002-08-20 | Oregon Health And Science University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
US6919067B2 (en) | 1991-09-13 | 2005-07-19 | Syngenix Limited | Compositions comprising a tissue glue and therapeutic agents |
AU677216B2 (en) * | 1992-07-27 | 1997-04-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Targeting of liposomes to the blood-brain barrier |
WO1994002178A1 (en) * | 1992-07-27 | 1994-02-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting of liposomes to the blood-brain barrier |
WO1994017821A1 (en) * | 1993-02-09 | 1994-08-18 | Basf Aktiengesellschaft | Use of thrombine inhibitors for controlling neurodegenerative diseases |
WO1995007092A1 (en) * | 1993-09-10 | 1995-03-16 | The University Of Medicine And Dentistry Of New Jersey | Blood-brain barrier transporters of neurological agents |
US6117454A (en) * | 1994-02-28 | 2000-09-12 | Medinova Medical Consulting Gmbh | Drug targeting to the nervous system by nanoparticles |
US7423010B2 (en) | 1994-05-19 | 2008-09-09 | Oregon Health & Science University | Nonporous microparticle-prodrug conjugates for treatment of infection |
US7166286B2 (en) | 1996-05-22 | 2007-01-23 | Viventia Biotech Inc. | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for prophylaxis and detection of cancers |
US6207153B1 (en) | 1996-05-22 | 2001-03-27 | Viventia Biotech, Inc. | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
US6569664B1 (en) | 1996-11-06 | 2003-05-27 | The Regents Of The University Of California | Native TNF receptor releasing enzyme |
US6858402B2 (en) | 1996-11-06 | 2005-02-22 | The Regents Of The University Of California | System for discovering and producing polypeptides that cause TNF receptor shedding |
US6573062B1 (en) | 1996-11-06 | 2003-06-03 | The Regents Of The University Of California | Method for obtaining modulators of TNF receptor releasing enzyme |
US7115722B1 (en) | 1997-05-22 | 2006-10-03 | Viventia Biotech, Inc. | Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers |
US7723056B1 (en) | 1997-10-16 | 2010-05-25 | The University Of Manchester | Particles |
US7510830B2 (en) | 2000-07-28 | 2009-03-31 | Cancer Research Technology Limited | Cancer treatment by combination therapy |
US10335224B2 (en) | 2000-08-17 | 2019-07-02 | Angiodynamics, Inc. | Method of destroying tissue cells by electroporation |
US7795232B1 (en) | 2000-08-25 | 2010-09-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
EP2281828A2 (en) | 2000-12-29 | 2011-02-09 | The Kenneth S. Warren Institute, Inc. | Compositions comprising modified erythropoietin |
US7396811B2 (en) | 2001-04-30 | 2008-07-08 | Zystor Therapeutics, Inc. | Subcellular targeting of therapeutic proteins |
US9814762B2 (en) | 2001-04-30 | 2017-11-14 | Biomarin Pharmaceutical Inc. | Targeted therapeutic proteins |
US8859498B2 (en) | 2001-04-30 | 2014-10-14 | Biomarin Pharmaceutical Inc. | Targeted therapeutic proteins |
US7858576B2 (en) | 2001-04-30 | 2010-12-28 | Zystor Therapeutics, Inc. | Method for targeting lysosomal enzymes |
US10300113B2 (en) | 2001-04-30 | 2019-05-28 | Biomarin Pharmaceutical Inc. | Targeted therapeutic proteins |
US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US8492337B2 (en) | 2001-04-30 | 2013-07-23 | Biomarin Pharmaceutical Inc. | Targeted therapeutic proteins |
US10463426B2 (en) | 2001-08-13 | 2019-11-05 | Angiodynamics, Inc. | Method for treating a tubular anatomical structure |
US7868040B2 (en) | 2001-09-03 | 2011-01-11 | Cancer Research Technology Limited | Anti-cancer combinations |
US7868039B2 (en) | 2001-09-03 | 2011-01-11 | Cancer Research Technology Limited | Anti-cancer combinations |
US7863320B2 (en) | 2001-09-03 | 2011-01-04 | Cancer Research Technology Limited | Anti-cancer combinations |
US7863322B2 (en) | 2001-09-03 | 2011-01-04 | Cancer Research Technology Limited | Anti-cancer combinations |
US7863321B2 (en) | 2001-09-03 | 2011-01-04 | Cancer Research Technology Limited | Anti-cancer combinations |
EP1446007A4 (en) * | 2001-10-16 | 2005-12-07 | Zystor Therapeutics Inc | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
EP1446007A1 (en) * | 2001-10-16 | 2004-08-18 | Symbiontics, Inc. | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
US7981864B2 (en) | 2001-10-16 | 2011-07-19 | Biomarin Pharmaceutical Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
US7462642B2 (en) | 2002-03-22 | 2008-12-09 | Cancer Research Technology Limited | Anti-cancer combinations |
US7217796B2 (en) | 2002-05-24 | 2007-05-15 | Schering Corporation | Neutralizing human anti-IGFR antibody |
US7851181B2 (en) | 2002-05-24 | 2010-12-14 | Schering Corporation | Neutralizing human anti-IGFR antibody |
US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US8207114B2 (en) | 2002-05-29 | 2012-06-26 | Biomarin Pharmaceutical Inc. | Targeted therapeutic proteins |
US7585893B2 (en) | 2002-11-01 | 2009-09-08 | Cancer Research Technology Limited | Anti-cancer composition comprising DMXAA or related compound |
US10188698B2 (en) * | 2003-04-28 | 2019-01-29 | Children's Hospital Medical Center | Saposin C-DOPS: a novel anti-tumor agent |
US20150125497A1 (en) * | 2003-04-28 | 2015-05-07 | Children's Hospital Medical Center | Saposin C-DOPS: A Novel Anti-Tumor Agent |
EP2274978A1 (en) | 2003-09-12 | 2011-01-19 | Tercica, Inc. | Methods for treatment of insulin-like growth factor-I(IGF-I) deficiency |
US8062886B2 (en) | 2003-11-12 | 2011-11-22 | Schering Corporation | Plasmid system for multigene expression |
US7326567B2 (en) | 2003-11-12 | 2008-02-05 | Schering Corporation | Plasmid system for multigene expression |
US8017735B2 (en) | 2003-11-21 | 2011-09-13 | Schering Corporation | Anti-IGFR1 antibody therapeutic combinations |
US7785856B2 (en) | 2004-02-10 | 2010-08-31 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
US7811562B2 (en) | 2004-12-03 | 2010-10-12 | Schering Corporation | Biomarkers for pre-selection of patients for anti-IGF1R therapy |
US8835654B2 (en) | 2004-12-22 | 2014-09-16 | Bhi Limited Partnership | Method and compositions for treating amyloid-related diseases |
US9988427B2 (en) | 2005-05-13 | 2018-06-05 | Charite Universitaetsmedizen-Berlin | Erythropoietin variants |
WO2006126208A2 (en) * | 2005-05-26 | 2006-11-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier |
US9943481B2 (en) | 2005-05-26 | 2018-04-17 | Biorest Ltd. | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier |
US10722463B2 (en) | 2005-05-26 | 2020-07-28 | Zuli Holdings Ltd. | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier |
EP2279726A3 (en) * | 2005-05-26 | 2012-06-20 | Biorest Ltd. | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier |
WO2006126208A3 (en) * | 2005-05-26 | 2007-09-20 | Yissum Res Dev Co | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier |
EP2540309A2 (en) | 2005-08-05 | 2013-01-02 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and uses thereof |
EP2594279A1 (en) | 2005-08-05 | 2013-05-22 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and uses thereof |
EP2371855A1 (en) | 2005-08-05 | 2011-10-05 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and uses thereof |
US10857109B2 (en) | 2006-10-12 | 2020-12-08 | Bellus Health, Inc. | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
US11020360B2 (en) | 2006-10-12 | 2021-06-01 | Bellus Health Inc. | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
US10238611B2 (en) | 2006-10-12 | 2019-03-26 | Bellus Health Inc. | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
US9499480B2 (en) | 2006-10-12 | 2016-11-22 | Bhi Limited Partnership | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
US8895303B2 (en) | 2006-11-13 | 2014-11-25 | Charite-Universitatsmedizin Berlin | Method of cell culture and method of treatment comprising a vEPO protein variant |
WO2008134828A2 (en) | 2007-05-04 | 2008-11-13 | Katholieke Universiteit Leuven | Tissue degeneration protection |
EP2933264A2 (en) | 2008-01-22 | 2015-10-21 | Araim Pharmaceuticals, Inc. | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
EP2274011A4 (en) * | 2008-04-17 | 2013-04-24 | Banyan Biomarkers Inc | An antibody bound synthetic vesicle containing active agent molecules |
EP2274011A2 (en) * | 2008-04-17 | 2011-01-19 | Banyan Biomarkers, Inc. | An antibody bound synthetic vesicle containing active agent molecules |
US9283051B2 (en) | 2008-04-29 | 2016-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
US10245105B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Electroporation with cooling to treat tissue |
US9598691B2 (en) | 2008-04-29 | 2017-03-21 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation to create tissue scaffolds |
US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
US9198733B2 (en) | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
US10959772B2 (en) | 2008-04-29 | 2021-03-30 | Virginia Tech Intellectual Properties, Inc. | Blood-brain barrier disruption using electrical energy |
US10828085B2 (en) | 2008-04-29 | 2020-11-10 | Virginia Tech Intellectual Properties, Inc. | Immunotherapeutic methods using irreversible electroporation |
US10828086B2 (en) | 2008-04-29 | 2020-11-10 | Virginia Tech Intellectual Properties, Inc. | Immunotherapeutic methods using irreversible electroporation |
US11890046B2 (en) | 2008-04-29 | 2024-02-06 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
US11453873B2 (en) | 2008-04-29 | 2022-09-27 | Virginia Tech Intellectual Properties, Inc. | Methods for delivery of biphasic electrical pulses for non-thermal ablation |
US11607271B2 (en) | 2008-04-29 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
US10537379B2 (en) | 2008-04-29 | 2020-01-21 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
US11737810B2 (en) | 2008-04-29 | 2023-08-29 | Virginia Tech Intellectual Properties, Inc. | Immunotherapeutic methods using electroporation |
US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US10470822B2 (en) | 2008-04-29 | 2019-11-12 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
US10154874B2 (en) | 2008-04-29 | 2018-12-18 | Virginia Tech Intellectual Properties, Inc. | Immunotherapeutic methods using irreversible electroporation |
US11655466B2 (en) | 2008-04-29 | 2023-05-23 | Virginia Tech Intellectual Properties, Inc. | Methods of reducing adverse effects of non-thermal ablation |
US10286108B2 (en) | 2008-04-29 | 2019-05-14 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation to create tissue scaffolds |
US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
US10245098B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Acute blood-brain barrier disruption using electrical energy based therapy |
US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
US9469683B2 (en) | 2008-05-07 | 2016-10-18 | Biomarin Pharmaceutical Inc. | Lysosomal targeting peptides and uses thereof |
US11351231B2 (en) | 2008-05-07 | 2022-06-07 | Biomarin Pharmaceutical Inc. | Lysosomal targeting peptides and uses thereof |
WO2010035261A2 (en) | 2008-09-29 | 2010-04-01 | Ben Gurion University Of The Negev Research And Development Authority | Amyloid beta-peptides and methods of use thereof |
WO2010108665A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
US10292755B2 (en) | 2009-04-09 | 2019-05-21 | Virginia Tech Intellectual Properties, Inc. | High frequency electroporation for cancer therapy |
US10448989B2 (en) | 2009-04-09 | 2019-10-22 | Virginia Tech Intellectual Properties, Inc. | High-frequency electroporation for cancer therapy |
US11707629B2 (en) | 2009-05-28 | 2023-07-25 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
US9764145B2 (en) | 2009-05-28 | 2017-09-19 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
EP3181582A1 (en) | 2009-11-26 | 2017-06-21 | InflaRx GmbH | Anti-c5a binding moieties with high blocking activity |
WO2011063980A1 (en) | 2009-11-26 | 2011-06-03 | Inflarx Gmbh | Anti-c5a binding moieties with high blocking activity |
EP3670532A1 (en) | 2009-11-26 | 2020-06-24 | InflaRx GmbH | Anti-c5a binding moieties with high blocking activity |
WO2011070177A2 (en) | 2009-12-11 | 2011-06-16 | Baltic Technology Development, Ltd. | Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators |
US8901129B2 (en) | 2009-12-11 | 2014-12-02 | Genecode As | Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators |
US11931096B2 (en) | 2010-10-13 | 2024-03-19 | Angiodynamics, Inc. | System and method for electrically ablating tissue of a patient |
WO2012061907A2 (en) | 2010-11-10 | 2012-05-18 | Katholieke Universiteit Leuven | Osteoclast activity |
EP3345545A1 (en) | 2011-04-21 | 2018-07-11 | The Regents of The University of California | Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles |
US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
WO2013093891A1 (en) | 2011-12-22 | 2013-06-27 | Nuvo Research Gmbh | Liposomal chlorite or chlorate compositions |
WO2014143614A1 (en) | 2013-03-11 | 2014-09-18 | Jan Remmereit | Lipid compositions containing bioactive fatty acids |
WO2014140934A2 (en) | 2013-03-11 | 2014-09-18 | Life Science Nutrition As | Natural lipids containing non-oxidizable fatty acids |
US9994641B2 (en) | 2013-12-25 | 2018-06-12 | Jcr Pharmaceuticals Co., Ltd. | Anti-human transferrin receptor antibody that passes through blood-brain barrier |
WO2015098989A1 (en) | 2013-12-25 | 2015-07-02 | Jcrファーマ株式会社 | Novel anti-transferrin receptor antibody that passes through blood-brain barrier |
EP3450557A1 (en) | 2013-12-25 | 2019-03-06 | JCR Pharmaceuticals Co., Ltd. | Novel anti-transferrin receptor antibody that passes through blood-brain barrier |
US11406820B2 (en) | 2014-05-12 | 2022-08-09 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
US10471254B2 (en) | 2014-05-12 | 2019-11-12 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
US10694972B2 (en) | 2014-12-15 | 2020-06-30 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
US11903690B2 (en) | 2014-12-15 | 2024-02-20 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
WO2018050848A1 (en) | 2016-09-15 | 2018-03-22 | Universität Stuttgart | Antigen binding protein against her3 |
WO2018087720A1 (en) | 2016-11-14 | 2018-05-17 | Novartis Ag | Compositions, methods, and therapeutic uses related to fusogenic protein minion |
US11723710B2 (en) | 2016-11-17 | 2023-08-15 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
US11464868B2 (en) | 2017-04-03 | 2022-10-11 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5A activity |
WO2018184739A1 (en) | 2017-04-03 | 2018-10-11 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of c5a activity |
EP3978523A1 (en) | 2017-04-03 | 2022-04-06 | InflaRx GmbH | Treatment of inflammatory diseases with inhibitors of c5a activity |
US11273225B2 (en) | 2017-04-03 | 2022-03-15 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
US11890349B2 (en) | 2017-04-03 | 2024-02-06 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5A activity |
EP4272821A2 (en) | 2017-04-03 | 2023-11-08 | InflaRx GmbH | Treatment of inflammatory diseases with inhibitors of c5a activity |
WO2018226992A1 (en) | 2017-06-07 | 2018-12-13 | Adrx, Inc. | Tau aggregation inhibitors |
WO2018234118A1 (en) | 2017-06-23 | 2018-12-27 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of c5a activity |
WO2019036725A2 (en) | 2017-08-18 | 2019-02-21 | Adrx, Inc. | Tau aggregation peptide inhibitors |
US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
WO2020055768A1 (en) | 2018-09-10 | 2020-03-19 | Cold Spring Harbor Laboratory | Methods for treating pancreatitis |
WO2020182384A1 (en) | 2019-03-11 | 2020-09-17 | Inflarx Gmbh | Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor |
US11952568B2 (en) | 2019-04-05 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of biphasic electrical pulses for non-thermal ablation |
WO2021190770A1 (en) | 2020-03-27 | 2021-09-30 | Inflarx Gmbh | INHIBITORS OF C5A FOR THE TREATMENT OF CORONA VIRUS Infection |
US11950835B2 (en) | 2020-06-29 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy |
US11957405B2 (en) | 2020-10-16 | 2024-04-16 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
Also Published As
Publication number | Publication date |
---|---|
CA2025907A1 (en) | 1991-03-22 |
AU6501390A (en) | 1991-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1991004014A1 (en) | Method for transporting compositions across the blood brain barrier | |
US5258499A (en) | Liposome targeting using receptor specific ligands | |
US6063400A (en) | Targeted liposomal constructs for diagnostic and therapeutic uses | |
US8303983B2 (en) | Targeted liposomal drug delivery system | |
JP3577312B2 (en) | Pharmaceutical compositions containing defined lipid systems | |
US5225212A (en) | Microreservoir liposome composition and method | |
EP0662820B1 (en) | Compositions for treatmewnt of inflamed tissues | |
JP2001510451A (en) | Ion carrier carrying weakly basic drug-liposome in the middle | |
US5366958A (en) | Localized delivery using fibronectin conjugates | |
CN100431609C (en) | Long circulation liposome with modified integrin and carried anticancer medicine for injection | |
JPH10502333A (en) | Vasoactive Intestinal polypeptide | |
IL96069A (en) | Liposome compositions for treating solid tumors | |
CA2141216A1 (en) | Targeting of liposomes to the blood-brain barrier | |
Vitols et al. | Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex | |
US7776819B2 (en) | Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization | |
WO1999059545A9 (en) | Targeted liposomal drug delivery system | |
Keshavarz et al. | CAR, a homing peptide, prolongs pulmonary preferential vasodilation by increasing pulmonary retention and reducing systemic absorption of liposomal fasudil | |
Sethi et al. | Liposomal vasoactive intestinal peptide | |
OA12210A (en) | Iron chelator delivery system. | |
US20050058697A1 (en) | Cell penetrating therapeutic agents | |
IE852602L (en) | Micellular particles | |
WO1987007150A1 (en) | Receptor-targeted drug delivery systems | |
Rubinstein et al. | Conformation and vasoreactivity of VIP in phospholipids: effects of calmodulin☆ | |
Crommelin et al. | Liposomes and immunoliposomes for controlled release or site specific delivery of anti-parasitic drugs and cytostatics | |
JP2817883B2 (en) | Highly complete liposomes and their formulations and uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB IT LU ML MR NL SE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |